HealthEquity (HQY)
(Delayed Data from NSDQ)
$80.98 USD
+1.22 (1.53%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $80.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$80.98 USD
+1.22 (1.53%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $80.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Zacks News
Why Is HealthEquity (HQY) Down 29.3% Since Last Earnings Report?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is HealthEquity (HQY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (HQY) Outperforming Other Medical Stocks This Year?
MEDP or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MEDP vs. HQY: Which Stock Is the Better Value Option?
Here's Why You Should Hold HealthEquity (HQY) Stock for Now
by Zacks Equity Research
HealthEquity's (HQY) fiscal third-quarter results hold promise while competition is stiff.
Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (HQY) Outperforming Other Medical Stocks This Year?
Why HealthEquity (HQY) Isn't Done Growing Earnings Yet
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider HealthEquity (HQY).
ESRX vs. HQY: Which Stock Is the Better Value Option?
by Zacks Equity Research
ESRX vs. HQY: Which Stock Is the Better Value Option?
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q3
by Zacks Equity Research
HealthEquity's (HQY) impressive results in Q3 can be attributed to solid growth in HSA Members. Its bullish guidance for fiscal 2019 further raises investors' optimism on the stock.
HealthEquity (HQY) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 12.00% and 1.06%, respectively, for the quarter ended October 2018. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will HSA Member Growth Aid HealthEquity's (HQY) Q3 Earnings?
by Zacks Equity Research
HealthEquity's (HQY) top line is likely to be driven by solid Health Savings Accounts (HSA) member growth in the fiscal third quarter. However, cutthroat competition in the niche space is concerning.
ESRX or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ESRX vs. HQY: Which Stock Is the Better Value Option?
Is HealthEquity (HQY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (HQY) Outperforming Other Medical Stocks This Year?
ESRX or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ESRX vs. HQY: Which Stock Is the Better Value Option?
Near-Term Outlook for Medical Services Industry Looks Bright
by Urmimala Biswas
Growing importance of efficient healthcare management is positioning the providers of medical services well to benefit.
Here's Why You Should Buy HealthEquity (HQY) Stock Right Now
by Zacks Equity Research
Strong presence in the HSA space and a solid guidance for fiscal 2019 make HealthEquity (HQY) a promising investment pick.
Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (HQY) Outperforming Other Medical Stocks This Year?
HealthEquity (HQY) Down 3.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teladoc Leads Telehealth Thanks to its Virtual Care Solution
by Zacks Equity Research
Teladoc's (TDOC) vast product portfolio, client base, tie-ups and acquisitions make it a leader in the telehealth industry.
Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (HQY) Outperforming Other Medical Stocks This Year?
Here's Why Momentum Investors Will Love HealthEquity (HQY)
by Zacks Equity Research
Does HealthEquity (HQY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Looking for a Growth Stock? Why It is Time to Focus on HealthEquity (HQY)
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider HealthEquity (HQY).
HealthEquity (HQY) Beats Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Strong HSA Member growth boosts HealthEquity's (HQY) results in Q2. A strong guidance raises investors??? optimism.
Can HSA Member Growth Drive HealthEquity's (HQY) Q2 Earnings?
by Zacks Equity Research
HealthEquity (HQY) is likely to register solid HSA member growth in the quarter to be reported.
HealthEquity (HQY) Q2 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.